EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that early trading in Q4 of the current financial year has again been materially higher than budget and at a run-rate in excess of already revised market forecasts, upgraded following the trading update provided on 7 October 2016.
The Company now believes that it will achieve revenues of at least £36.5m and adjusted EBITDA for the year ending 31 December 2016 of at least £5.5m, therefore exceeding current market forecasts. The strong performance of the business is due to organic growth.
In addition, the Company announces that cash generation continues to be strong and now expects to be close to breakeven if not cash positive by the year end, and then cash positive in the first quarter, again ahead of the board’s previous expectations.
The announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.
|EKF Diagnostics Holdings plc
Julian Baines, CEO
Richard Evans, Finance Director and COO
|00 44 29 2071 0570
|Panmure Gordon (UK) Limited
|00 44 20 7886 2500|
Walbrook PR Limited
|00 44 20 7933 8780 or email@example.com
00 44 7980 541 893
00 44 7584 391 303